Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Valproic-acid | hsa00030 | Pentose phosphate pathway | 1.69E-02 | 2 | P60891, P37837 | PRPS1, TALDO1 | More | | Valproic-acid | hsa00071 | Fatty acid degradation | 2.45E-02 | 3 | P11310, P28332, P33121 | ACADM, ADH6, ACSL1 | More | | Valproic-acid | hsa00220 | Arginine biosynthesis | 1.43E-02 | 2 | P05089, P49448 | ARG1, GLUD2 | More | | Valproic-acid | hsa00250 | Alanine, aspartate and glutamate metabolism | 4.51E-02 | 1 | P51649 | ALDH5A1 | More | | Valproic-acid | hsa00480 | Glutathione metabolism | 3.29E-04 | 4 | Q9UJ14, Q16772, P09211, P30041 | GGTL3, GSTA3, GSTP1, PRDX6 | More | | Valproic-acid | hsa00531 | Glycosaminoglycan degradation | 3.03E-02 | 1 | P15586 | GNS | More | | Valproic-acid | hsa00620 | Pyruvate metabolism | 3.19E-02 | 2 | P40926, P14550 | MDH2, AKR1A1 | More | | Valproic-acid | hsa00860 | Porphyrin and chlorophyll metabolism | 1.69E-02 | 2 | P36551, P30043 | CPOX, BLVRB | More | | Valproic-acid | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.46E-03 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | | Valproic-acid | hsa00982 | Drug metabolism - cytochrome P450 | 1.06E-02 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | | Valproic-acid | hsa00983 | Drug metabolism - other enzymes | 1.72E-02 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | | Valproic-acid | hsa01100 | Metabolic pathways | 8.43E-03 | 11 | P35790, Q16772, P09211, Q9UJ14, P30041, P40926, Q7KZN9, P15121, Q9UHK6, Q86VZ5, Q9BQB6 | CHKA, GSTA3, GSTP1, GGTL3, PRDX6, MDH2, COX15, AKR1B1, AMACR, SGMS1, VKORC1 | More | | Valproic-acid | hsa01200 | Carbon metabolism | 4.29E-02 | 4 | P04406, O14521, Q9P2R7, Q02252 | GAPDH, SDHD, SUCLA2, ALDH6A1 | More | | Valproic-acid | hsa01230 | Biosynthesis of amino acids | 3.59E-02 | 3 | P60891, Q99707, P37837 | PRPS1, MTR, TALDO1 | More | | Valproic-acid | hsa01524 | Platinum drug resistance | 4.58E-03 | 4 | P04637, P48023, Q16772, P09211 | TP53, FASLG, GSTA3, GSTP1 | More | | Valproic-acid | hsa03008 | Ribosome biogenesis in eukaryotes | 1.88E-02 | 3 | O14980, O60832, Q9BVP2 | XPO1, DKC1, GNL3 | More | | Valproic-acid | hsa03013 | RNA transport | 2.35E-05 | 10 | O14980, P52298, O14893, P61326, Q7Z3B4, P35658, Q14152, Q14240, P23588, Q9Y6A5 | XPO1, NCBP2, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF4A2, EIF4B, TACC3 | More | | Valproic-acid | hsa03040 | Spliceosome | 6.29E-03 | 7 | Q14562, O43143, O75940, O75494, Q07955, Q13243, O75643 | DHX8, DHX15, SMNDC1, FUSIP1, SFRS1, SFRS5, ASCC3L1 | More | | Valproic-acid | hsa04012 | ErbB signaling pathway | 3.69E-02 | 3 | P16333, P19174, P01106 | NCK1, PLCG1, MYC | More | | Valproic-acid | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | | Valproic-acid | hsa04062 | Chemokine signaling pathway | 1.83E-02 | 8 | P25024, P25025, P09341, P19875, P42338, P19174, P63218, P50151 | CXCR1, CXCR2, CXCL1, CXCL2, PIK3CB, PLCG1, GNG5, GNG10 | More | | Valproic-acid | hsa04064 | NF-kappa B signaling pathway | 2.15E-02 | 7 | P14778, P19174, Q04759, P06239, P09341, P19875, Q06643 | IL1R1, PLCG1, PRKCQ, LCK, CXCL1, CXCL2, LTB | More | | Valproic-acid | hsa04068 | FoxO signaling pathway | 6.45E-03 | 2 | P48023, Q96BR1 | FASLG, SGK3 | More | | Valproic-acid | hsa04070 | Phosphatidylinositol signaling system | 2.11E-02 | 4 | P19174, P0DP23, P49619, P27987 | PLCG1, CALM1, DGKG, ITPKB | More | | Valproic-acid | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | | Valproic-acid | hsa04136 | Autophagy - other | 5.92E-03 | 2 | O94817, Q9H1Y0 | ATG12, ATG5 | More | | Valproic-acid | hsa04151 | PI3K-Akt signaling pathway | 4.21E-03 | 3 | P48023, P04637, Q96BR1 | FASLG, TP53, SGK3 | More | | Valproic-acid | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | Valproic-acid | hsa04360 | Axon guidance | 4.39E-02 | 4 | P16333, P20827, O95631, P19174 | NCK1, EFNA1, NTN1, PLCG1 | More | | Valproic-acid | hsa04610 | Complement and coagulation cascades | 3.19E-02 | 1 | P0C0L4 | C4A | More | | Valproic-acid | hsa04612 | Antigen processing and presentation | 8.21E-03 | 5 | P26715, P26717, Q07444, Q13241, P01732 | KLRC1, KLRC2, KLRC3, KLRD1, CD8A | More | | Valproic-acid | hsa04613 | Neutrophil extracellular trap formation | 4.62E-02 | 6 | P19174, P11215, Q93077, P62807, O60814, P14598 | PLCG1, ITGAM, HIST1H2AC, HIST1H2BC, H2BC12, NCF1 | More | | Valproic-acid | hsa04640 | Hematopoietic cell lineage | 1.37E-02 | 7 | P14778, P27930, P11215, P25063, P07766, P01732, P09564 | IL1R1, IL1R2, ITGAM, CD24, CD3E, CD8A, CD7 | More | | Valproic-acid | hsa04650 | Natural killer cell mediated cytotoxicity | 2.45E-07 | 13 | P19174, P06239, O60880, P20963, P42338, P48023, Q13241, P26718, O14931, P26717, Q07444, Q14953, P26715 | PLCG1, LCK, SH2D1A, CD247, PIK3CB, FASLG, KLRD1, KLRK1, NCR3, KLRC2, KLRC3, KIR2DS5, KLRC1 | More | | Valproic-acid | hsa04658 | Th1 and Th2 cell differentiation | 6.40E-08 | 10 | Q04759, P07766, P20963, P09693, P19174, P06239, P23771, Q9UL17, P14784, Q13761 | PRKCQ, CD3E, CD247, CD3G, PLCG1, LCK, GATA3, TBX21, IL2RB, RUNX3 | More | | Valproic-acid | hsa04659 | Th17 cell differentiation | 1.02E-05 | 10 | Q04759, P19174, P06239, P14784, P14778, Q9UL17, P23771, P07766, P09693, P20963 | PRKCQ, PLCG1, LCK, IL2RB, IL1R1, TBX21, GATA3, CD3E, CD3G, CD247 | More | | Valproic-acid | hsa04660 | T cell receptor signaling pathway | 1.19E-05 | 11 | Q04759, P42338, O95267, Q08881, P19174, P07766, P20963, P09693, P01732, Q13191, P06239 | PRKCQ, PIK3CB, RASGRP1, ITK, PLCG1, CD3E, CD247, CD3G, CD8A, CBLB, LCK | More | | Valproic-acid | hsa04710 | Circadian rhythm | 1.67E-02 | 2 | Q16526, Q9Y478 | CRY1, PRKAB1 | More | | Valproic-acid | hsa04722 | Neurotrophin signaling pathway | 2.27E-02 | 2 | P48023, P04637 | FASLG, TP53 | More | | Valproic-acid | hsa04744 | Phototransduction | 7.59E-03 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Valproic-acid | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.24E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | Valproic-acid | hsa04920 | Adipocytokine signaling pathway | 4.31E-02 | 2 | Q9Y478, Q96RR4 | PRKAB1, CAMKK2 | More | | Valproic-acid | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | Valproic-acid | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Valproic-acid | hsa04974 | Protein digestion and absorption | 1.52E-02 | 1 | P02452 | COL1A1 | More | | Valproic-acid | hsa05034 | Alcoholism | 2.05E-02 | 5 | P0DP23, P62873, Q93077, P62807, O60814 | CALM1, GNB1, HIST1H2AC, HIST1H2BC, H2BC12 | More | | Valproic-acid | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.78E-03 | 5 | P09341, P19875, P19174, P25024, P25025 | CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | | Valproic-acid | hsa05133 | Pertussis | 2.63E-02 | 2 | P10145, P0C0L4 | IL8, C4A | More | | Valproic-acid | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | Valproic-acid | hsa05140 | Leishmaniasis | 3.52E-02 | 4 | P14598, P11215, P42224, P29350 | NCF1, ITGAM, STAT1, PTPN6 | More | | Valproic-acid | hsa05146 | Amoebiasis | 2.37E-05 | 9 | P09341, P19875, P14778, P27930, P42338, P11215, P05089, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, PIK3CB, ITGAM, ARG1, ACTN1, CTSG | More | | Valproic-acid | hsa05160 | Hepatitis C | 3.81E-02 | 2 | P04637, P48023 | TP53, FASLG | More | | Valproic-acid | hsa05164 | Influenza A | 3.48E-02 | 2 | Q9GZY0, P48023 | NXF2; NXF2B, FASLG | More | | Valproic-acid | hsa05168 | Herpes simplex virus 1 infection | 4.54E-03 | 4 | P04637, Q9GZY0, P48023, P98182 | TP53, NXF2; NXF2B, FASLG, ZNF200 | More | | Valproic-acid | hsa05203 | Viral carcinogenesis | 4.62E-02 | 3 | Q12933, P42229, Q15283 | TRAF2, STAT5A, RASA2 | More | | Valproic-acid | hsa05204 | Chemical carcinogenesis | 5.46E-03 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | | Valproic-acid | hsa05214 | Glioma | 3.69E-02 | 3 | P0DP23, P19174, O75293 | CALM1, PLCG1, GADD45B | More | | Valproic-acid | hsa05219 | Bladder cancer | 4.51E-02 | 1 | P04637 | TP53 | More | | Valproic-acid | hsa05231 | Choline metabolism in cancer | 4.95E-02 | 3 | Q9Y259, P19174, P49619 | CHKB, PLCG1, DGKG | More | | Valproic-acid | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.32E-04 | 8 | P42338, O95267, P19174, P07766, P20963, P09693, P06239, Q04759 | PIK3CB, RASGRP1, PLCG1, CD3E, CD247, CD3G, LCK, PRKCQ | More | | Valproic-acid | hsa05322 | Systemic lupus erythematosus | 1.57E-02 | 4 | P08311, P62807, Q16778, P12814 | CTSG, HIST1H2BC, HIST2H2BE, ACTN1 | More | | |